Furthermore, a remarkable and durable response to entrectinib Alk-Trk inhibitory therapy has been reported in an infant with therapy-resistant, advanced stage 4 metastatic NB exhibiting a molecular profile consistent with TrkAIII expression and activation [29]. Here, NTRK1 is linked to neuroblastoma.